Pfizer cut to A+ by Fitch Ratings on debt repayment; Alexion wins FDA nod on new use for Soliris;

@FiercePharma: While the EU takes more time to weigh its Cephalon deal, Teva agrees to buy out Japanese JV partner for $150M. Story | Follow @FiercePharma

> Pfizer had its credit ratings cut by Fitch Ratings to A+ for failing to pay off more debt since its 2009 buyout of Wyeth. Report

> Alexion Pharmaceuticals won FDA approval for broader use of its Soliris drug, to treat a rare disorder, atypical hemolytic uremic syndrome. Report

> Dr. Reddy's Laboratories has called off its proposed deal to buy a portfolio of prescription drugs sold in Russia and the surrounding region from JB Chemicals & Pharmaceuticals. Report

> Orchid Pharmaceuticals said a fire at its facility in Chennai, India, struck a research lab and as such won't affect manufacturing operations. Report

> Japan's Asahi Kasei Pharma won regulatory approval to market a subcutaneous form of Teribone, an osteoporosis treatment in its home market. Report

> Chugai Pharmaceuticals, which has the rights to market Roche's Avastin in Japan, won a new indication for the drug in inoperable or recurrent breast cancer. Report

> Alkermes got an analyst upgrade in the wake of its acquisition of Elan's drug technologies unit. Report

> Sweden's Medivir tapped Maris Hartmanis as its new president and CEO; Hartmanis most recently CEO of the specialty pharma BioPhausia. Report

> Astellas Pharma and Optimer Pharmaceuticals said European regulators gave an initial nod to its Dificlir drug designed to treat C. difficile infection. Release

Biotech News

 @FierceBiotech: PacBio wants to offer sequencing machine users new cloud computing capabilities. Company is working with Cycle Computing. Story | Follow @FierceBiotech

 @RyanMFierce: Cancer drug shortages keep keep getting worse, bad trend for developers and patients. Report | Follow @RyanMFierce

 @MaureenFierce: Reading: Downsizing trend leaves pharma without the kinds of employees it needs. Story via @Pharmalot | Follow @MaureenFierce

> Elevation Pharma nabs $17M, recruits two key players. Report

> Report: FDA readies release of long-awaited rules on biosimilars. Item

> Roche R&D chief Garaud affirms $10B peak potential for HDL drug. Report

> Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field. News

Medical Device News

 @FierceMedDev: Neat! Diagnostic Development Unit Is A Star Trek-Style Sick Bay Bed via PSFK. Report | Follow @FierceMedDev

> Delcath taps Miao as CFO. Story

> Occlutech CEO scores win against St Jude-AGA Medical. Item

> Mela receives approvable letter for cancer device. Report

> Bausch + Lomb makes exec moves. News

> PENTAX launches first HD video bronchoscope. Story

Biotech IT News

> NextDocs expands to West Coast. Report

> PacBio reaches for cloud tech amid biz slump. Report

> Brain Resource scores $10M, opens SF office. News

> NIH backs tech linking trial data, patient records. Story

> Computational analysis points to potential HIV targets. Article

And Finally... A district judge tossed a lawsuit against Eli Lilly, in which a convicted murderer blamed the crime on Prozac. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.